PMID- 32202252

OWN - NLM
STAT- Publisher
LR - 20200323
IS - 1658-3876 (Print)
DP - 2020 Mar 12
TI - Haploidentical bone marrow transplant with posttransplant cyclophosphamide
for
sickle cell disease: An update.
LID - S1658-3876(20)30025-X [pii]
LID - 10.1016/j.hemonc.2020.01.002 [doi]
AB - Hematopoietic cell transplant (HCT) can cure both children and adults with
sickle
cell disease. Outcomes have historically been poor for the vast majority of
patients who lack a matched sibling donor. However, the development of
haploidentical HCT (haplo-HCT) with high doses of posttransplant
cyclophosphamide
(PTCy) has allowed for curative long-term potential with favorable
transplant-related outcomes, though this has not obviated the potential for
graft
rejection from human leukocyte antigen mismatch and repeated red blood cell
transfusions. Accordingly, multiple strategies have been developed to improve
outcomes, the majority of which are based on the Johns Hopkins platform from
2012. Presently, we aim to discuss results from pertinent studies and compare
outcomes with the two most recent approaches involving either thiotepa plus
200-cGy total body irradiation or 400-cGy total body irradiation. Direct
comparisons are required to determine the optimized curative potential.
Transplant-eligible patients must be referred to tertiary medical centers for
consideration of haplo-HCT.
CI - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Patel, Dilan A
AU - Patel DA
AD - Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry
Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical
Center, Nashville, TN, USA.
FAU - Akinsete, Adeseye M
AU - Akinsete AM
AD - College of Medicine, Division of Pediatric Hematology & Oncology, Lagos
University Teaching Hospital, Idi-Araba, Lagos, Nigeria.
FAU - de la Fuente, Josu
AU - de la Fuente J
AD - Department of Paediatrics, St. Mary's Hospital, Imperial College, London,
United
Kingdom.
FAU - Kassim, Adetola A
AU - Kassim AA
AD - Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry
Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical
Center, Nashville, TN, USA. Electronic address: adetola.kassim@vumc.org.
LA - eng
PT - Journal Article
PT - Review
DEP - 20200312
PL - England
TA - Hematol Oncol Stem Cell Ther
JT - Hematology/oncology and stem cell therapy
JID - 101468532
SB - IM
OTO - NOTNLM
OT - Cyclophosphamide
OT - Haploidentical transplant
OT - Sickle cell disease
OT - Thiotepa
OT - Total body irradiation
COIS- Declaration of Competing Interest The authors do not have any competing
interests
to disclose.
EDAT- 2020/03/24 06:00
MHDA- 2020/03/24 06:00
CRDT- 2020/03/24 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/03/24 06:00 [entrez]
PHST- 2020/03/24 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
AID - S1658-3876(20)30025-X [pii]
AID - 10.1016/j.hemonc.2020.01.002 [doi]
PST - aheadofprint
SO - Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20)30025-X. doi:
10.1016/j.hemonc.2020.01.002.